Major Oncology Breakthrough Shows Promising Tumor Treatment Results

Groundbreaking Study Reveals CRB-701's Potential for Nectin-4 Positive Tumors.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

The world of oncology research has witnessed a major breakthrough with Corbus Pharmaceuticals' CRB-701 (SYS6002), a next-generation Nectin-4 targeting antibody-drug conjugate. It has shown promising safety and…